Short answer
Akebia Therapeutics, Inc. (AKBA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $37M (down 37.2% year over year) with net income of −$14M.
Q3 2026 key financials · XBRL
- Revenue
- $37M
- −37.2% YoY · −24.9% QoQ
- Net income
- −$14M
- −2758.1% YoY · −61.1% QoQ
- Operating margin
- -31.1%
- EPS (diluted)
- −$0.05
- −600.0% YoY · −25.0% QoQ
Source: XBRL data from the Akebia Therapeutics, Inc. (AKBA) Q3 2026 10-Q on SEC EDGAR. USD.
Akebia Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $36.9M, down 37% YoY from $58.8M
- Net loss $14.4M vs $0.5M net income YoY, operating margin -31.1% vs 7.6%
- Worst performer Auryxia revenue $20.0M, down 53% YoY from $42.5M
- Cash $160.2M including restricted cash at September 30, down from $186.5M year-end 2025
- Nine-month operating cash flow $(15.4)M vs $36.9M, outlook pressured by generics and lower Vafseo pricing in 2027
Risk Factors
- Newly triggered regulatory risk: 2027 ESRD Rule creates quarterly Vafseo reimbursement adjustments after TDAPA expiration on January 1, 2027
- Most material commercial update: Teva’s March 2026 generic Auryxia approval caused significant sales-volume reduction
- Regulatory safety risk: Vafseo carries a boxed warning for increased death, myocardial infarction, stroke, and thromboembolic risks
- Near-term market risk: Vafseo revenue was lower than anticipated in Q3 2026 as customers reduced inventory ahead of TDAPA expiration
- Financial liquidity risk: $159.3 million cash depends on refinancing debt before principal payments begin January 1, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Akebia Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.